A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221799

Enrollment

Registered

2012-05-25

Start date

2012-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's Lymphoma

Interventions

investigational material(s) Generic name etc : MLN8237 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with relapsed and/or refractory Non-Hodgkin's Lymphoma that is diagnosed hisologically or cytologically 2) Patients with radiologically or clinically measurable diseases 3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1

Exclusion criteria

Exclusion criteria: 1) Prior treatment with Aurora kinase inhibitors 2) Prior treatment of allogeneic hematopoietic stem cells transplant, or organ transplant 3) Patients with brain or cerebrospinal invasion 4) Major surgery within 14 days prior to enrollment 5) Serious infection or infection that requires intravenous antibiotics within 14 days prior to enrollment. 6) Simultaneously diagnosed with or treated for another malignancy, or having a clinical history of primary malignancy in another organ(s)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026